Microscopic Observation Drug Susceptibility Assay for Tuberculosis Screening before Isoniazid Preventive Therapy in HIV‐Infected Persons | Zendy

Krishna P. Reddy | Zendy; Mark F. Brady | Zendy; Robert H. Gilman | Zendy; Jorge Coronel | Zendy; Marcos Ñavincopa | Zendy; Eduardo Ticona | Zendy; Gonzalo Chávez | Zendy; Eduardo Sánchez | Zendy; Christian Rojas | Zendy; Lely Solari | Zendy; Jorge Valencia | Zendy; Yvett Pinedo | Zendy; Carlos Benites | Zendy; Jon S. Friedland | Zendy; David Moore | Zendy

Open Access

Microscopic Observation Drug Susceptibility Assay for Tuberculosis Screening before Isoniazid Preventive Therapy in HIV‐Infected Persons

Author(s) -

Krishna P. Reddy,

Mark F. Brady,

Robert H. Gilman,

Jorge Coronel,

Marcos Ñavincopa,

Eduardo Ticona,

Gonzalo Chávez,

Eduardo Sánchez,

Christian Rojas,

Lely Solari,

Jorge Valencia,

Yvett Pinedo,

Carlos Benites,

Jon S. Friedland,

David Moore

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/651081

Subject(s) - medicine , isoniazid , tuberculosis , drug , human immunodeficiency virus (hiv) , pharmacotherapy , sida , virology , immunology , pharmacology , viral disease , pathology

Active tuberculosis (TB) must be excluded before initiating isoniazid preventive therapy (IPT) in persons infected with human immunodeficiency virus (HIV), but currently used screening strategies have poor sensitivity and specificity and high patient attrition rates. Liquid TB culture is now recommended for the detection of Mycobacterium tuberculosis in individuals suspected of having TB. This study compared the efficacy, effectiveness, and speed of the microscopic observation drug susceptibility (MODS) assay with currently used strategies for TB screening before IPT in HIV-infected persons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research